Infectious Disease Control

/C O R R E C T I O N -- Korean Ginseng Research Institute/

We are advised by the client that there are several changes in the release content. The complete, corrected version of the news release issued on 21-Oct-2021 by Korean Ginseng Research Institute over PR Newswire is as follows: Red Ginseng's possible Vaccine Adjuvant Effect gave out from Korean Gin...

2021-10-22 17:20 1074

/C O R R E C T I O N -- Korean Ginseng Research Institute/

In the news release, Korean Ginseng Research Institute Announces potential COVID-19 Vaccine Adjuvant Effect of Red Ginseng, issued20-Oct-2021 by Korean Ginseng Research Institute over PR Newswire, we are advised by the company that the headline, should read "Korean Ginseng Research Institute A...

2021-10-22 16:28 1320

Educating children about good hygiene is key to helping reduce future health threats

LONDON, Oct. 22, 2021 /PRNewswire/ -- The COVID-19 pandemic has heightened awareness globally of the role that hygiene measures like handwashing can play in infection prevention. Handwashing at high-risk moments is a proven and cost-effective way of reducing common infections by up to 50%. Resea...

2021-10-22 14:01 521

Aero HygenX Partners with Ethiopian Airlines for Deployment of Autonomous UV-C Disinfecting Solution

* With hygiene in sharp focus, industry support for Aero HygenX continues to grow * Chemical-free disinfection via UV-C light offers a safer work environment for staff and is gentler on aircraft interiors * A global problem requires global solutions: It is the intention of Aero HygenX to ...

2021-10-21 21:57 950

INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives

Memorandum of Understanding builds on recent regulatory authorization from INVIMAto conduct INNOVATE Phase 3 trial for INO-4800, INOVIO's COVID-19 vaccine candidate,in Colombia Colombia authorization augments recent regulatory authorizations from Brazil, the Philippines and Mexico to commence it...

2021-10-21 20:00 895

BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine

VANCOUVER, BC, Oct. 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has filed with the United States Patent & Trademark Office ("USPTO") a provisional patent application for its haptenized viral antigen va...

2021-10-20 21:24 1533

Bill & Melinda Gates Foundation Commits up to $120 Million to Accelerate Access to COVID-19 Drug for Lower-Income Countries, Calls on Other Donors to Mobilize Resources

Financial commitment aims to secure dedicated, low-cost supply of molnupiravir, if the drug is authorized by regulators; builds on long-term efforts to increase access to tests, treatments, vaccines SEATTLE, Oct. 20, 2021 /PRNewswire/ -- The Bill & Melinda Gates Foundation announced today a comm...

2021-10-20 13:29 843

CARB-X Funds the 3rd Round of Debiopharm's Targeted Antibiotic Program to Combat Resistant N. gonorrhoeae Infections

LAUSANNE, Switzerland and BOSTON, Oct. 19, 2021 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453...

2021-10-19 09:00 904

Novavax to Participate in World Vaccine Congress Europe

GAITHERSBURG, Md., Oct. 16, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Vivek Shinde, M.D., Vice President, Clinical Development, will deliver a...

2021-10-16 04:39 2392

Phase II Data Of Medigen COVID-19 Vaccine, Reviewed And Published In The Lancet Respiratory Medicine

TAIPEI, Oct. 15, 2021 /PRNewswire/ -- The Lancet Respiratory Medicine , one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (...

2021-10-15 18:36 1176

Interim Results Of A Pioneering Combination Study In Argentina With More Than 1,000 Participants Confirm The One-shot Sputnik Light Vaccine (The First Component Of The Sputnik V Vaccine) Is An Effective Universal Booster For Vaccines Produced By AstraZeneca, Sinopharm, Moderna And Cansino Inducing Strong Immune Response And Showing High Safety Profile. Combination Of AstraZeneca And Sputnik Light Vaccines Showed High Immunogenicity Results.

* One-shot Sputnik Light is the first component of the Sputnik V vaccine, the world's first registered vaccine against coronavirus. Sputnik V pioneered the heterogeneous boosting approach (a "vaccine cocktail" using human adenovirus serotype 26 as the first component and human adenovirus seroty...

2021-10-15 05:26 1540

More community healthcare needed in COVID-19 planning as chronic disease rates pressure hospitals

* Allied health experts call for more community-based care models to cope with COVID surge * 'Long COVID' shown to affect one in four people who catch the virus, leading to an increase in chronic disease sufferers and the need for more rehabilitation services. The UK now has two million cases...

2021-10-13 05:00 912

Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease

DURHAM, N.C. and BEIJING, Oct. 9, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health...

2021-10-09 03:07 4012

RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

TEL AVIV, Israel and RALEIGH, N.C., Oct. 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported new data from the opaganib global Phase 2/3 study in hospitalized patien...

2021-10-04 21:24 8299

Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021

DURHAM, N.C.and BEIJING, Oct. 4, 2021 /PRNewswire/ -- Brii Biosciences  Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health ...

2021-10-04 08:00 1877

Impact Credit Solutions and Bank Central Asia partner to offer financing to the Indonesian healthcare sector

SINGAPORE, Sept. 30, 2021 /PRNewswire/ -- Bank Central Asia (BCA), a leading Indonesian commercial bank, and Impact Credit Solutions (ICS) have partnered to offer affordable financing to the Indonesian healthcare sector during the COVID-19 pandemic. BCA has committed toparticipating in the US$40 ...

2021-09-30 09:00 1038

Zymo Research Pays it Forward With Their Commitment to Eradicate the COVID-19 Pandemic in India

DNA/RNA Shield – DirectDetect™ reagent eliminates RNA extraction for rapid deployment of COVID-19 tests in affected countries IRVINE, Calif., Sept. 28, 2021 /PRNewswire/ -- Zymo Research has donated one million COVID-19 test kits that include its newDNA/RNA Shield - DirectDetect™ reagent and col...

2021-09-28 14:57 796

Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy

DURHAM, N.C. and BEIJING, Sept. 28, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public heal...

2021-09-28 08:00 1554

LEAD Horizon: How travelers in Austria gargle against the corona virus

Austrian success model with gold standard tests is possible worldwide VIENNA, Sept. 27, 2021 /PRNewswire/ -- Vienna got through the pandemic better in comparison to other European cities - thanks to a specially developed PCR test by the Austrian company LEAD Horizon, which is already used in 13 ...

2021-09-27 09:00 1018

Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases

- Pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine - NanoFlu™ vaccine candidate induced significantly enhanced cell-mediated immune responses - NanoFlu was well-tolerated with a comparable safety profile...

2021-09-24 08:47 2899
12345 ... 52